US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 18:43:50 Source:opinionsViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Philippines blames China for loss of giant clams in disputed shoal and urges environmental inquiry
Next:Sweden beats France, Britain relegated after losing to Norway at hockey worlds
You may also like
- 'Constantly learning' Imanaga off to impressive start with the Chicago Cubs
- Leaders highlight goals, tasks in talks
- Kyle Larson is on the pole for the 3rd NASCAR Cup race in a row, this time in Texas
- Chinese vice premier stresses preparation for spring farming
- Minnesota Uber and Lyft driver pay package beats deadline to win approval in Legislature
- China's top legislature concludes standing committee session
- Xi stresses developing new quality productive forces
- Chinese premier stresses nurturing new drivers for high
- ‘The Blue Angels,’ filmed for IMAX, puts viewers in the ‘box’ with the elite flying squad